Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Evaluation of macro aggregated albumin solution for 99mTc MAA

Jennifer Ow, GT Dolan and Wendy Galbraith
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 490;
Jennifer Ow
1Nuclear Pharmacy University of Oklahoma College of Pharmacy Oklahoma City OK United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GT Dolan
1Nuclear Pharmacy University of Oklahoma College of Pharmacy Oklahoma City OK United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Galbraith
2Pharmaceutical Sciences University of Oklahoma College of Pharmacy Oklahoma City OK United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

490

Objectives Only one commercial kit for the preparation of 99mTc macro aggregated albumin (MAA) is available in the US. The current method of preparing a particle dependent dosage uses the reconstituted MAA solution to be labeled with 99mTc. Information on the stability of this solution is lacking. Our objective was to evaluate the stability of MAA solution using radiochemical purity (RCP) and particle size of 99mTc MAA.

Methods Over 12 months, commercially available MAA reaction vials were reconstituted with normal saline and the solution repackaged into vials containing 500,000 particles per 1 mL in a commercial nuclear pharmacy setting in accordance with USP 797. Vials were stored at 2°C to 8°C for 3 to 14 days before labeling with 99mTc. Contents were drawn into 3 mL BD syringes and stored at 20°C to 25°C for up to 24 hours. RCP and particle size were evaluated initially and at 24 hours using a method previously described. Correlations between 99mTc mole fractions and storage times to RCP were calculated.

Results 36 samples were analyzed. Four different lots of MAA were used; n=3, 15, 3, and 12 respectively. The solution was stored for an average of 8 days (SD ± 4 days). The average activity was 34.2 mCi (SD ± 3.8 mCi). The average 99mTc mole fraction was 0.41 (range 0.17 to 0.59). Storage temperature was 5°C ± 2°C. The mean RCP of the 99mTc-MAA was 97.7% (range 85.5% to 100%) initially and 96.2% (range 38% to 99.9%) at 24 hours. The size of the particles ranged from 10 to 150 micrometers with 90% being 10 to 50 micrometers. There was a correlation between storage time and RCP (r = -0.25) and 99mTc mole fraction (r = 0.2).

Conclusions Taking into consideration elution quality and storage conditions, repackaging MAA does not appear to affect the stability of the MAA solution to form stable 99mTc-MAA. While 34 of our samples met USP RCP parameters of 蠅 90%, two did not. In addition there may be procedures that require higher RCP limits than USP.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of macro aggregated albumin solution for 99mTc MAA
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of macro aggregated albumin solution for 99mTc MAA
Jennifer Ow, GT Dolan, Wendy Galbraith
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 490;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of macro aggregated albumin solution for 99mTc MAA
Jennifer Ow, GT Dolan, Wendy Galbraith
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 490;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy

  • 68Ga radiolabeling and quality control in a small-scale radiopharmacy- working amidst constraints in developing countries
  • 44Sc-PSMA-617 for pretherapeutic dosimetry prostate cancer
  • Prostate cancer diagnosis: Radiochemical characterization of 68Ga-PSMA
Show more Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire